Anzeige
Mehr »
Sonntag, 29.03.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

NASDAQ Biotech 

WKN:  ISIN:  
Markt oder Branche auswählen:

Aktuelle News zu Aktien im NASDAQ Biotech

  • 24 h
  • 7 Tage
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:  Alle DE EN
LeserMedien
10:30BioNTech: Wichtiger Termin am Montag - Was das für Ihr Depot bedeutet
09:50Sonntag-Meldung zu BIONTECH SE ADR: Jetzt wird's ernst!6
SaBiogen meldet positive Phase-2-Daten für Haut-Lupus-Wirkstoff3
SaBiogen Inc.: Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity550In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear...
► Artikel lesen
SaIncyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting555 Phase 3 data from the STOP-HS program demonstrate povorcitinib's substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). ...
► Artikel lesen
SaBiogen reports positive Phase 2 results for lupus skin drug4
SaRoivant Sciences: New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis1
SaAlumis reports Phase 3 psoriasis trial results for envudeucitinib1
SaAlumis meldet überzeugende Phase-3-Ergebnisse für Psoriasis-Wirkstoff Envudeucitinib2
SaAlumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis1
SaSanofi Reports Positive Phase 3 Results For Amlitelimab In Atopic Dermatitis419PARIS (dpa-AFX) - Sanofi SA (SNY, SNYNF,SAN.PA) announced encouraging results from three Phase 3 clinical trials-COAST 1, COAST 2, and SHORE-evaluating amlitelimab, a fully human non-T cell...
► Artikel lesen
SaSanofi meldet positive Phase-3-Daten für Medikament gegen atopische Dermatitis8
SaArcutis: Studiendaten belegen Wirksamkeit von Roflumilast-Creme bei Säuglingen mit Neurodermitis4
SaSanofi reports positive phase 3 data for atopic dermatitis drug6
SaArcutis presents trial data on roflumilast cream for infants2
SaSanofi: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session1.446AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed...
► Artikel lesen
SaKymera Therapeutics, Inc.: Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting1
SaArcutis Biotherapeutics, Inc.: Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting3
SaProtagonist Therapeutics: Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology Annual Meeting958One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults further...
► Artikel lesen
SaBioCryst strebt Milliardenumsatz an und stärkt HAE-Portfolio mit Navenibart6
Weiter >>